-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Historical Evolution
May 2025
Koyuan Pharmaceutical (Guangzhou) Co., Ltd. was officially established.
February 2025
Koyuan Pharmaceutical (Shanghai) Co., Ltd. was officially established.
June 2024
Metformin hydrochloride, palonosetron hydrochloride, and rotigotine APIs have been re-certified by the FDA; methylene blue API has been certified by the FDA.
November 2023
Signed an equity cooperation agreement with Beijing Nuokangda Pharmaceutical, which became the Beijing R&D center.
April 2023
Successfully listed on the Shenzhen Stock Exchange's ChiNext board, stock code 301281.SZ
December 2021
Sales of the anti-diabetic raw material metformin hydrochloride exceeded 100 million for the first time.
September 2021
Awarded honorary titles such as Specialized, Refined, and Unique Enterprise of Shandong Province and Gazelle Enterprise of Shandong Province.
December 2019
The hypoglycemic drug ingredient, Gliclazide, achieved over 100 million in revenue for the first time as a single product.
July 2019
Shandong Linyi Pharmaceutical Co., Ltd. became a wholly-owned subsidiary.
October 2017
The first digital factory (Factory 4) has officially started production, marking a new stage in digital transformation and upgrading.
March 2016
Koyuan Pharmaceutical successfully listed on the NEEQ
December 2012
Achieved a profit exceeding 10 million yuan for the first time in a year.
June 2005
The active pharmaceutical ingredient, Glezetide, has received the company's first international certification - the Korean MFDS certification, opening up the company's path to international development.
December 2004
Shandong Keyuan Pharmaceutical Co., Ltd. was established. It obtained 15 raw material drug product GMP certificates at once.
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline